Pharmaceuticals, Biotechnology and Life Sciences
4D pharma Wednesday said that its clinical study with Merck to test MRx0518 combined with Keytruda further support its continued investment into our oncology franchise.
Merck has received positive EU CHMP opinion for two new regimens of Keytruda (pembrolizumab) as first-line ttreatment for metastatic or…
Merck has received EU CHMP positive opinion for investigational V920 ebola Zaire vaccine for protection Against ebola virus disease.
Merck has issued its corporate responsibility report, illustrating its approach to long-Term sustainability for business and society.
Nevakar, ophthalmology specialist pharmaceutical company has entered into a $17.5 million product financing agreement with an affiliate of H.I.G. Capital Partners, L.P. for the continued development of five differentiated, sterile injectable products.
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Michael Nally,…
Merck’s trial of Keytruda plus chemotherapy, followed by adjuvant Keytruda as monotherapy, which was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the neoadjuvant treatment of patients with high-risk, early-stage TNBC plus chemotherapy, resulted in a statistically significant increase in pathological complete response (pCR) versus chemotherapy.
“The results of this Keytruda plus Lenvima study are a welcome development in the treatment of women with advanced endometrial cancer, a patient group with an unmet medical need,” said Dr. Vicky Makker, principal investigator and medical oncologist, Memorial Sloan Kettering Cancer Center.
Merck’s biopharmaceutical branch, EMD Serono, and Pfizer will present clinical activity of treatment with Bavencio across multiple tumor types and patient populations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.
USAFDA has given approvals for Merck’s Pifeltro and Delstrigo for certain HIV-1 patients, based on fFindings from the Phase 3 DRIVE-SHIFT Trial, Merck said on Friday in a press release.